CytoDyn Inc (OTCPK:CYDY)
$ 0.148 -0.00976 (-6.19%) Market Cap: 147.02 Mil Enterprise Value: 185.80 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 26/100

Cytodyn Inc Dr. Nader Pourhassan, CytoDyn's CEO, Addresses The False Claims Made By STAT News Transcript

Jul 31, 2020 / NTS GMT
Release Date Price: $4.97 (-7.20%)
Christine Corrado
Proactive - Moderator

Hello, and welcome back to Proactive New York. I'm Christine Corrado. With me right now is Nader Pourhassan, CEO at CytoDyn. Nader, great to see you. How are you?

Nader Pourhassan
CytoDyn, Inc. - CEO

I am doing great. It's a beautiful day and thank you for having me.

Christine Corrado
Proactive - Moderator

Nader, a lot to get to today. First off, you announced positive coronavirus clinical trial results on your shareholders' call meeting yesterday. However, a report came out from a healthcare publication called STAT, suggesting that your description of CytoDyn's leronlimab data points hasn't met its goal in treating coronavirus patients. What's your response to that?

Nader Pourhassan
CytoDyn, Inc. - CEO

So our goal is to create data that FDA gets to see and have FDA make a decision on those. We don't pay attention to this kind of false report usually. But we are an OTC company, and we have an obligation to refuse the statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot